Swiss dental startup vVardis has taken a step toward going public in the United States, filing for an initial public offering (IPO) on the New York Stock Exchange. The company, best known for its Curodont line of products, is aiming for a valuation of roughly $4.4 billion, according to the filing. It plans to raise up to $228.6 million by selling 9.5 million shares at a price range of $21 to $24 each.
The move comes at a tricky time for new listings. US markets have been volatile, with investors showing less appetite for risk. IPOs, which often rely on strong demand from growth-focused investors, can struggle when market sentiment shifts quickly. vVardis is betting that its story—drill-free dentistry—will stand out enough to attract buyers even in a cautious environment.
What is vVardis and what does it do?
vVardis is a Swiss company that focuses on minimally invasive dental care. Its flagship product, Curodont, is designed to repair early-stage tooth decay without the need for traditional drilling. Instead of removing decayed tissue with a drill, the treatment aims to remineralize and rebuild the tooth's surface, offering a less painful and more conservative alternative to standard fillings.
The company is essentially trying to sell public investors on a new approach to a very common problem. Tooth decay affects billions of people worldwide, and the dental industry has long relied on drilling and filling as the standard treatment. If vVardis can convince dentists and patients that its products are effective and cost-efficient, it could tap into a large market. However, the company is still in the early stages of commercializing its technology, and profitability is not guaranteed.
Why is the IPO market so jumpy?
The broader IPO environment has been uneven. After a strong stretch in late 2024 and early 2025, many companies have found it harder to go public as interest rates remain elevated and investors grow more selective. Volatility in the stock market, driven by concerns about inflation, economic growth, and geopolitical tensions, has made it harder for companies to price their shares attractively.
For vVardis, the timing is a double-edged sword. On one hand, a successful IPO could signal that investors are still willing to back innovative healthcare companies. On the other, if the deal stumbles, it could reinforce the cautious mood. The company's pricing range suggests it is aiming for a moderate valuation, but even that may be a tough sell if market conditions worsen.
What does this mean for investors?
For everyday investors, the vVardis IPO is a reminder that new listings come with significant risks. Unlike established companies with years of financial history, startups often have limited revenue, unproven business models, and high uncertainty. vVardis is no exception—it is still working to scale its products and build a customer base.
Investors should also consider the broader context. The IPO market has been described as "jumpy," meaning that shares of newly listed companies can be especially volatile in the first few weeks of trading. If you're thinking about participating in the IPO, it's important to understand that you may not be able to sell your shares immediately, and the price could swing sharply.
That said, the dental care sector is a large and growing market, and vVardis's drill-free approach could appeal to patients and dentists looking for less invasive options. If the company executes well, it could become a meaningful player. But as with any IPO, there's no guarantee of success.
What to watch next
Investors will be watching how the market reacts to vVardis's pricing and whether the deal gets fully subscribed. If the IPO is successful, it could encourage other healthcare startups to test the waters. If it fails, it might add to the caution already present in the market.
For now, vVardis's fate rests on whether investors believe in the drill-free dentistry story enough to pay $21 to $24 per share. The company's ability to raise the full $228.6 million will be a key indicator of market sentiment. As always, it's wise to do your own research and consider your risk tolerance before investing in any IPO.
